Advertisement
A vs SYK
Which Stock Would AI Choose? Agilent Technologies (A) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Different industries, different drivers: A (Agilent Technologies) serves life sciences, diagnostics, and applied chemical markets, while SYK (Stryker) is a global medical technology and surgical equipment leader.
- Momentum diverges sharply: Agilent has posted strong recent gains on accelerating biopharma demand, while Stryker shares have lagged as investors weigh recovery from a cybersecurity disruption and a leadership transition.
- Earnings quality differs: Agilent exceeded guidance with margin expansion, while Stryker beat estimates but tightened, rather than raised, its full-year outlook.
- Valuation gap is notable: Stryker trades below its own five-year historical average, whereas Agilent's multiple reflects renewed growth expectations.
- Risk profiles contrast: Agilent carries exposure to instrument replacement cycles and China, while Stryker faces execution risk tied to operational recovery and acquisition integration.
Introduction
Investors weighing growth against stability often compare companies from adjacent healthcare-related industries to understand where capital is rotating. This stock comparison examines Agilent Technologies, a life sciences and diagnostics instrument maker, against Stryker, a diversified medical technology firm best known for orthopaedics, surgical equipment, and robotics. Although both serve healthcare end markets, their business models, growth drivers, and recent price behavior differ considerably. Growth-oriented traders may find Agilent's momentum appealing, while defensive investors focused on large-cap quality and recurring procedure demand may gravitate toward Stryker. Understanding their relative performance and market positioning helps clarify which profile better fits current conditions.
A Overview and Recent Performance
Agilent Technologies (A), originally spun out of Hewlett-Packard in 1999, provides measurement and analytical instruments across life sciences, diagnostics, and applied chemical markets. Its revenue is weighted toward the biopharmaceutical, chemical, and advanced materials segments, with sizable exposure to both the United States and China.
Recent market activity has favored the stock. Agilent's fiscal third-quarter results showed revenue of roughly $1.88 billion and core revenue growth above 7%, exceeding the high end of guidance. Earnings per share (EPS, the profit allocated to each outstanding share) rose about 14% year over year, helped by double-digit growth in the pharma business and more than 70% growth in GLP-1-related revenue tied to a popular class of metabolic medicines. The company also cited a strong instrument replacement cycle, a tenth consecutive quarter with book-to-bill above one, and China revenue that surprised to the upside. These factors have supported positive sentiment and upward analyst rating revisions in recent weeks.
SYK Overview and Recent Performance
Stryker (SYK) is one of the world's largest medical technology companies, with a portfolio spanning orthopaedic implants, medical and surgical equipment, neurotechnology, and the Mako robotic-assisted surgery platform. Its roughly $100 billion-plus market capitalization reflects a long track record of acquisitions and consistent procedure-driven demand.
Recent performance has been more mixed. A cybersecurity incident in the spring disrupted production and shipping, contributing to a weak first quarter and elevated remediation costs. Second-quarter results marked a recovery, with revenue up about 9% and adjusted EPS rising nearly 18%, while gross and operating margins expanded. However, the company tightened rather than raised its full-year outlook, and shares declined in after-hours trading following the report. Investors are also digesting a planned chief executive succession, with the current CEO transitioning to Executive Chair in early 2027. These events have left the stock trading below its historical valuation despite improving fundamentals.
Trending AI Robots
For traders seeking a data-driven alternative to manual analysis, Tickeron's Trending AI Robots page offers a curated view of the platform's most compelling automated strategies. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with distinct trading styles, timeframes, performance statistics, and watchlists. Because not every bot suits every market environment, only those best aligned with current conditions earn a place in the Trending AI Robots section. This selection process helps traders quickly identify strategies demonstrating relative strength, consistency, or adaptability. Explore the Trending AI Robots page to see which automated approaches are currently leading the platform.
Head-to-Head Comparison
The two companies occupy different positions within healthcare. Agilent is a "picks and shovels" supplier to laboratories and drug developers, generating revenue from instruments, consumables, and services. Stryker sells directly into hospitals and surgical centers, with recurring demand tied to procedures and an installed base of robotic systems and implants. Agilent's growth leans on research spending cycles and product replacement; Stryker's leans on procedure volumes, demographics, and robotics adoption.
On recent momentum, Agilent has clearly outperformed, with accelerating organic growth and favorable earnings surprises driving positive revisions. Stryker's rebound is real but clouded by the cyber disruption, a vascular supply constraint, and the CEO transition. Risk factors also differ: Agilent faces exposure to China, the biopharma funding cycle, and tariff dynamics, while Stryker faces execution risk around recovery, integration of recent acquisitions, and cybersecurity resilience.
Market sentiment has shifted accordingly. Agilent's relative strength and analyst upgrades signal growing conviction, whereas Stryker's below-average valuation and tighter guidance reflect a more cautious posture. Neither profile is objectively superior; they represent different trade-offs between cyclical growth and large-cap stability.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely tilt toward A (Agilent Technologies) in the current environment. The stock demonstrates more consistent trend strength, accelerating organic growth, expanding margins, and positive analyst revisions, all of which are characteristics AI models typically weigh favorably. SYK offers attractive valuation and improving fundamentals, but its trend remains clouded by operational recovery and leadership transition uncertainty. This assessment is probabilistic rather than definitive: AI signals reflect current data and can shift quickly as conditions evolve. Traders should treat this as one analytical input among many rather than a standalone recommendation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and SYK is a StrongBuy.
Momentum Indicator for A turns positive, indicating new upward trend
A saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 61 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +4.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where A advanced for three days, in 188 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 141 of 209 cases where A Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Bearish Trend Analysis
The 10-day RSI Indicator for A moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 21 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 75%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Moving Average Convergence Divergence Histogram (MACD) for A turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 28 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where A declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
A broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. A’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.658) is normal, around the industry mean (66.046). P/E Ratio (34.163) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.447) is also within normal values, averaging (3.473). Dividend Yield (0.006) settles around the average of (0.002) among similar stocks. P/S Ratio (5.910) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. A’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
SYK in upward trend: price rose above 50-day moving average on October 20, 2026
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 48 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.910) is normal, around the industry mean (2.874). P/E Ratio (31.560) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
A | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 91 | 76 | |
SMR RATING 1..100 | 45 | 52 | |
PRICE GROWTH RATING 1..100 | 5 | 56 | |
P/E GROWTH RATING 1..100 | 36 | 83 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for SYK (76) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as A (91) in the Biotechnology industry. This means that SYK’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as SYK (52) in the Medical Specialties industry. This means that A’s stock grew similarly to SYK’s over the last 12 months.
A's Price Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for SYK (56) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
A's P/E Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for SYK (83) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than SYK’s over the last 12 months.
| A | SYK | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 75% | 1 day ago 58% |
| Stochastic ODDS (%) | 1 day ago 71% | 1 day ago 50% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 53% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 52% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 56% |
| TrendMonth ODDS (%) | 1 day ago 63% | 1 day ago 50% |
| Advances ODDS (%) | 2 days ago 62% | 3 days ago 56% |
| Declines ODDS (%) | 4 days ago 63% | 9 days ago 52% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 67% | 1 day ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 5 bearish.
- SYK’s TA Score: 4 bullish, 5 bearish.
Price Growth
A (@Medical Specialties) experienced а -0.95% price change this week, while SYK (@Medical/Nursing Services) price change was +4.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.29%. For the same industry, the average monthly price growth was -6.63%, and the average quarterly price growth was +42.53%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
Reported Earning Dates
A is expected to report earnings on Nov 23, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (-3.29% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with BRKR. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then BRKR could also see price increases.